This Week in Health Funding: 5 Deals
$295 million landed across five healthcare startups the week of July 21 - and the pattern of where the money went tells operators exactly what investors believe is broken.
A physician sits in a reading room in Cleveland. Before she touches a single chart, an AI agent has already triaged her queue, flagged a coronary risk from an incidental scan, and routed three patients to telemedicine. That is not a pilot. That is production in 2026.
This week in healthcare funding did not produce a single blockbuster clinical AI IPO or a moonshot drug delivery company. What it produced was something quieter and more important: five checks written to companies solving the operational gut-punches of healthcare. Revenue cycle waste. Agentic workflow gaps. Medicare payment infrastructure. Remote chronic care delivery. Pharmacy fill-rate failures.
$295 million total. Five deals. One very clear thesis.
The collective signal from investors this week was not "we believe in clinical AI." It was "we believe healthcare's biggest cost sink is operations, and we are funding the companies attacking it."
Here is what closed, why it matters, and what it means for health system executives, FQHC leaders, radiologists, and investors who need to understand where the capital is going.
1. Candid Health: $120M Series D - The RCM Inflection Point
Candid Health raised $120 million in a Series D round led by Sixth Street Growth, with participation from Oak HC/FT, 8VC, and Y Combinator. The round was announced July 22, 2026, and values the company at three times its Series C valuation from February 2025.
The company builds autonomous revenue cycle management software. Its platform automates the full claims lifecycle - eligibility verification, prior authorization, claim submission, denial management, and payment posting - across more than 200 healthcare organizations.
📊 The U.S. healthcare system spends an estimated $280 billion annually on revenue cycle management. Administrative waste accounts for $760 billion of all U.S. healthcare spending, the largest single category of preventable cost in the system.
Candid Health's bet is that most of this spending is the result of process failures, not complexity. Insurance rule changes, payer-specific workflows, documentation requirements - these are solvable with software. The question was always whether the margin profile would support a venture-scale business.
The answer, apparently, is yes. Tripling in valuation with 200+ healthcare organization clients means Candid Health has cleared the most important hurdle in enterprise health tech: retention. Health systems do not switch billing vendors casually. When they renew, it signals the product works.
The broader implication is significant. Revenue cycle automation has historically been the unglamorous cousin of clinical AI. No one writes breathless articles about a better claims scrubber. But Sixth Street Growth wrote a $120 million check for one. That reframes the market.
For health system CFOs watching their revenue cycle costs consume 15 to 25 percent of net revenue, this round signals that the automation tools are mature enough to deploy at scale. The era of boutique RCM consulting firms is ending. Autonomous systems are replacing it.
2. Pearl Health: $110M - Betting on the ACO Wave
Pearl Health raised $110 million in a combined equity and debt financing: a $50 million Series C led by Andreessen Horowitz, with Viking Global Investors, AlleyCorp, and Ulysses Capital, alongside a $60 million credit facility led by Trinity Capital.
Pearl manages approximately $3.6 billion in annualized medical spend across more than 10,000 providers in over 40 states, covering approximately 275,000 Medicare beneficiaries. The company reached profitability in 2025 and projects $500 million in gross savings through the end of 2026.
📊 CMS's ACO LEAD Model, launching January 1, 2027, represents a 10-year commitment through 2036 - the longest ACO program in Medicare history. It pulls specialists into shared risk for the first time and targets dual-eligible and complex chronic populations specifically.
Pearl's value proposition is infrastructure. Primary care physicians caring for Medicare patients inside ACO arrangements need data pipelines, risk stratification models, care gap alerts, and documentation tooling to actually capture value-based savings. Pearl provides that layer.
The credit facility is as meaningful as the equity. A $60 million credit line from Trinity Capital signals that Pearl has the revenue contracts and balance sheet to service debt. That is a sign of commercial maturity most health tech companies do not reach until late stage.
For FQHC leaders and independent primary care practices, Pearl's growth reflects the capital that is flowing toward value-based care infrastructure. The ACO model is not going away - it is expanding. Organizations that build the internal capability to participate in risk arrangements will have access to revenue streams that fee-for-service providers do not.
3. Bunkerhill Health: $25M Series B - The Health System AI Agent Market
Bunkerhill Health closed a $25 million Series B led by Khosla Ventures, with continued participation from Sequoia Capital, Felicis, Optum Ventures, and Y Combinator. The total raised since founding is $55 million.
The company's product is called Carebricks: a platform that lets health systems build and deploy their own AI agents rather than buying point-tool solutions from vendors. Instead of purchasing a vendor AI for prior auth, a separate tool for scheduling, and another for care coordination, health systems use Carebricks to build agents tuned to their own workflows, data, and protocols.
Bunkerhill now works with 15 health systems - including Cleveland Clinic, Mayo Clinic, Ballad Health, Intermountain Health, Sentara Health, Endeavor Health, and the University of Texas Medical Branch - and grew revenue 20-fold in the past year.
📊 The 20x revenue growth figure deserves attention. In enterprise health tech, 2x annual growth is strong. 5x is exceptional. 20x reflects either a very small starting base or extraordinary product-market fit. At 15 health systems including Cleveland Clinic and Mayo, it suggests the latter.
The Carebricks model directly challenges the premise of traditional health IT vendors. Epic's App Orchard, Oracle Health's partner ecosystem, and dozens of point-tool vendors all assume that health systems want to buy pre-built tools. Bunkerhill's bet is that health systems with strong IT organizations want to build their own - they just need a platform to do it.
This is the agentic AI inflection point playing out in real time. Health systems are not waiting for vendors to ship generic AI tools. The systems that have the resources are building custom agents for their specific patient populations and workflows. Bunkerhill provides the infrastructure to do that without starting from scratch.
4. TytoCare: $25M+ Growth Round - Remote Care for Complex Patients
TytoCare closed a growth round of more than $25 million led by Insight Partners, with participation from HOOP, OliveTree, OrbiMed, Qumra Capital, and Qualcomm Ventures. The company simultaneously announced the appointment of Adam Pellegrini as Chief Executive Officer.
TytoCare makes FDA-cleared remote physical examination devices and AI software. Its technology enables clinicians to conduct remote examinations of the heart, lungs, ears, skin, and abdomen with clinical-grade accuracy. The growth round is paired with a strategic repositioning: the company is pivoting from a general telehealth product to focused AI-first clinical enablement for patients with chronic and complex disease.
📊 Approximately 129 million Americans - 51.8 percent of U.S. adults - have at least one chronic condition. High-acuity chronic disease patients (CHF, COPD, diabetes, CKD) account for a disproportionate share of healthcare spending and generate the most avoidable hospitalizations.
The CEO transition and strategic pivot are the more significant signals here. Pellegrini comes with a background in digital health and care enablement. The repositioning toward complex chronic care reflects where payer and health system demand is concentrated. General telehealth is commoditizing. Specialty virtual care with clinical-grade diagnostics is not.
For pulmonologists and cardiologists managing high-risk populations, TytoCare's pivot is directly relevant. Remote auscultation and examination tools that can detect early decompensation in a CHF patient at home are a different category than a video call with a thermometer. The Insight Partners check reflects a belief that this segment has pricing power the general telehealth market does not.
5. Plazza: $15M Series A - Pharmacy Access as Infrastructure
Plazza raised $15 million in a Series A co-led by Accel, Elevation Capital, and Nexus Venture Partners, with participation from All In Capital and Better Capital. The company was founded in 2024 by Aman Priyadarshi, a former Zomato executive, and operates in Bengaluru, India.
Plazza builds technology-enabled neighborhood pharmacies that deliver medicines within 15 to 30 minutes. Where a typical local pharmacy in India stocks approximately 5,000 items, a Plazza store stocks more than 40,000, achieving a prescription fulfillment rate exceeding 95 percent compared to an industry average of 50 to 60 percent.
📊 Plazza grew its gross merchandise value 27-fold between June 2025 and March 2026 - a nine-month window. The company operated two stores at funding and plans to reach 20 in Bengaluru by year-end 2026.
The Plazza deal is included in this week's roundup not because it is a U.S. market play - it is not - but because the underlying problem it is solving is global, including in the United States. Prescription abandonment rates in the U.S. reach 20 to 30 percent for new prescriptions, driven by cost, convenience, and fill-rate failures. In low-income urban neighborhoods served by FQHCs, the rate is higher.
The Plazza model - hyper-local pharmacy infrastructure with AI-driven inventory intelligence and rapid delivery - is a blueprint that will arrive in U.S. markets. Accel and Nexus are not writing checks to geography. They are writing checks to a proven unit economic model in a large market.
Deep Dive: The Operational Infrastructure Thesis
The five deals this week collectively reveal a clear investor thesis: healthcare's most fundable problem in 2026 is operational infrastructure, not clinical novelty.
Three of the five companies - Candid Health, Pearl Health, and Bunkerhill Health - do not primarily care for patients. They care for the systems that care for patients. Billing automation. Value-based payment infrastructure. Agentic workflow tooling. These are the invisible layers on which clinical care runs, and they are catastrophically inefficient.
The scale differential is instructive. Candid Health ($120M) and Pearl Health ($110M) are 4 to 8 times larger than the other rounds. Investors writing nine-figure checks in healthcare today are writing them to companies with demonstrated revenue at scale, not to companies with clinical promise.
The broader market context makes this pattern clearer. Digital health VC has hit $7.4 billion in 2026, on track for $80.1 billion across all healthcare venture - a 14 percent increase over 2025. But the number of funding rounds has declined 47 percent, to just 237. Capital is concentrating. Fewer companies are raising. The ones that do raise are raising more.
Fifty percent of all digital health capital in the first half of 2026 landed in rounds of $100 million or more. The market has bifurcated. On one side: institutional-scale companies raising institutional-scale checks. On the other: early-stage companies raising seed and Series A rounds that may never bridge to the growth stage.
For health system strategists and FQHC leaders, this bifurcation matters practically. The vendor ecosystem is thinning. Companies that raised Series A rounds in 2022 and 2023 at inflated valuations are failing to raise growth capital. Products you built workflows around may not exist in 24 months. Concentration is accelerating.
What Operational AI Actually Does
The three operational infrastructure companies this week - Candid, Pearl, Bunkerhill - share a common architecture: they sit between the clinical system and the financial system, extracting value from gaps that humans and legacy software cannot bridge.
Candid Health extracts value from the gap between what a payer's rules say and what a provider's team can process manually. Prior auth denials, incorrect codes, submission errors - each one is a revenue leak. Autonomous RCM software captures that leak systematically.
Pearl Health extracts value from the gap between what CMS pays in fee-for-service Medicare and what CMS pays in value-based ACO arrangements. The spread is large - potentially tens of thousands of dollars per beneficiary per year for complex patients - and it requires AI infrastructure to capture.
Bunkerhill Health extracts value from the gap between what a health system's care protocols say should happen and what actually happens across thousands of daily patient encounters. Agentic AI closes that gap without requiring staff to close it manually.
The pattern is consistent: all three companies are turning documented operational failures into addressable software problems. The failures are not new. The software is.
The Agentic Shift
Bunkerhill Health's $25 million Series B deserves separate attention because it signals a structural shift in how health systems will buy technology over the next decade.
The traditional model was: vendors build products, health systems buy them. Epic builds scheduling. A vendor builds prior auth automation. Another vendor builds care gap alerts. The health system integrates them through APIs and lives with the seams.
The emerging model is different. Health systems - at least the largest ones - are building their own agents on shared infrastructure. They define the workflow. They train the agent on their own data. They deploy and iterate without a vendor's product roadmap blocking them.
Bunkerhill's Carebricks platform is the infrastructure layer for this model. Its deployment at Cleveland Clinic, Mayo, and Intermountain suggests the largest health systems in the country are no longer waiting for vendors to ship AI tools. They are building.
The implication for smaller health systems and FQHCs is significant. If the large systems build differentiated AI agents and the mid-market relies on vendor products, the operational and quality gap between health system tiers will widen. This is already happening in radiology AI adoption data. It will happen in operational AI next.
What This Means For You
For FQHC executives and community health center leaders:
Revenue cycle complexity is your largest controllable cost target. Candid Health's Series D at 200+ health org clients signals that autonomous RCM is ready for community health center deployment. Evaluate now.
Pearl Health's Medicare ACO footprint covers 40+ states. If your FQHC serves a significant Medicare population, the ACO LEAD Model launching January 1, 2027 is a revenue opportunity, not just a regulatory event.
Bunkerhill's model is designed for health systems with IT resources. If you lack that infrastructure, your near-term path is vendor procurement. Prioritize vendors with demonstrated workflow integration and retention data.
Pharmacy abandonment at your panel affects your clinical outcomes and your gap closure rates. The Plazza model signals that rapid-delivery pharmacy infrastructure is being built at scale globally. Watch for U.S. market entrants applying this model to FQHC service areas.
For health system administrators and CMOs:
The 47 percent decline in funding rounds is a vendor risk signal. Audit your tech stack for companies that raised Series A or B rounds between 2021 and 2023 and have not yet reached profitability or raised follow-on capital. Those companies are at elevated risk.
TytoCare's pivot to complex chronic care reflects real demand. If your system manages CHF, COPD, or CKD populations, remote examination technology with clinical-grade diagnostics is now funded and commercially available. Evaluate it against your avoidable readmission rates.
Agentic AI is moving from pilot to production at Cleveland Clinic and Mayo. Schedule a strategic review of your AI roadmap against the Carebricks model. The question is whether you want to build or buy.
For radiologists and pulmonologists:
TytoCare's remote pulmonary examination tools are directly relevant to your patient population. Remote auscultation and COPD monitoring in the home setting reduces the gap between symptom onset and clinical intervention. Evaluate integration with your existing care pathways.
The operational AI wave documented this week will reach radiology workflows next. Autonomous prior auth submission for imaging studies (CPT 71250, 0721T, 75577) is the Candid Health model applied to your revenue cycle. It is coming.
For healthcare investors and founders:
The capital concentration data is a filter, not a funding crisis. If you are building operational infrastructure with demonstrated revenue and retention, this is the best funding environment in three years. If you are building clinical AI without workflow integration proof, the market will not rescue you.
Plazza's 27x GMV growth in nine months is the benchmark for what investors need to see at Series A. Not pilots. Not letters of intent. Deployed revenue at scale.
The Pearl Health credit facility structure is worth studying. Equity plus debt in a single round signals commercial maturity and avoids dilution at growth stage. This hybrid structure is becoming standard for health tech companies with recurring revenue.
Closing
The week of July 21, 2026 was not a week of moonshots. It was a week of infrastructure.
Five investors looked at healthcare's most persistent failures - revenue cycle waste, Medicare payment complexity, workflow automation gaps, remote care access, pharmacy fill-rate - and wrote nine-figure checks to companies with proven solutions.
The thesis underneath all five deals is the same: healthcare's biggest cost problems are not clinical. They are operational. And operational problems, at scale, respond to software.
The companies that thrive in this environment are not the ones with the most impressive clinical AI demo. They are the ones that have embedded themselves so deeply into health system workflows that replacement is more expensive than renewal.
That is the bar. Candid Health, Pearl Health, and Bunkerhill Health have cleared it. TytoCare is repositioning to clear it. Plazza is building toward it.
What are you building toward?
Reply to this email with what you are seeing in your market. We read everything.
About the Author
Jonathan Govette is the Co-Founder and CEO of Oatmeal Health, an AI lung cancer diagnostic company catching cancers earlier in the communities that need it most. Oatmeal uses AI to identify unscreened high-risk patients, navigate them to care, and score every lung CT for malignancy risk - billed under CPT 0721T. Stage I survival is 77%. Stage IV is 9%. We work in FQHCs because that gap is largest there.
Jonathan writes daily about radiology, pulmonology, AI diagnostics, health policy, hospital operations, and healthcare startups.
Subscribe to stay ahead of healthcare's most important shifts. Weekly deep-dives on AI, radiology, health policy, FQHCs, and the business of healthcare - written for operators, clinicians, and investors who want the signal, not the noise. Subscribe at oatmealhealthjonathangovette.substack.com
Key References
Candid Health Series D announcement: Sixth Street Growth, BusinessWire, July 22, 2026 - https://www.businesswire.com/news/home/20260721951537/en/Candid-Health-Raises-%24120M-Led-by-Sixth-Street-Growth-to-Fuel-Autonomous-Revenue-Cycle-Management-in-Healthcare
Bunkerhill Health Series B announcement: BusinessWire / Fortune, July 16, 2026 - https://www.businesswire.com/news/home/20260716806874/en/Bunkerhill-Health-Raises-$55-Million-to-Help-Health-Systems-Turn-Their-Best-Ideas-into-Reality
TytoCare growth round and CEO announcement: PR Newswire / Insight Partners, July 15, 2026 - https://www.prnewswire.com/news-releases/tytocare-names-adam-pellegrini-as-ceo-and-closes-25m-growth-round-to-scale-ai-first-clinical-enablement-platform-302825623.html
Pearl Health $110M Series C: Axios / Modern Healthcare, July 7, 2026 - https://www.modernhealthcare.com/health-tech/mh-pearl-health-funding-round/
Digital health VC H1 2026 ($7.4B): Rock Health / Modern Healthcare 2026 - https://www.modernhealthcare.com/health-tech/mh-digital-health-vc-funding-2026-rock-health/